Chimeric Protein Targeting for Blood-Brain Barrier Repair After Stroke
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Brain injuries and central nervous system disorders, such as ischemic stroke and degenerative disorders, result in nerve cell death and damage, leading to disabling and irreversible cognitive and sensorimotor degradation, with existing treatments lacking effective mitigation of oxidative damage and repair mechanisms.
Innovation Solution
Administration of a chimeric protein comprising a targeting domain with specific mutations, an activator domain with reduced IGF-1 receptor activation, and a half-life modulator, which is administered via bolus injection to target and stimulate the phosphorylation of AKT pathways, repair the blood-brain barrier, and deliver pro-survival signals to injured brain tissue.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type IGF-1 is used as the activator domain, then strong activation of IGF-1 receptor occurs, but non-specific activation and off-target effects increase
Solution Approach 1:
The patent applies local quality by creating a variant of IGF-1 with specific amino acid mutations (E3R, Y31A) that locally alter the binding interface properties. This modifies the receptor interaction characteristics to achieve selective activation of IGF-1 receptor while reducing non-specific activation, thereby resolving the contradiction between strong activation and specificity.
2Reliability
If the chimeric protein is designed with high targeting specificity, then delivery to injured tissue is improved, but the protein half-life decreases
Solution Approach 1:
The patent segments the chimeric protein into distinct functional domains: a targeting domain (Annexin A5 variant) that provides specificity for injured tissue, a linker region, and an activator domain (IGF-1 variant). This segmentation allows each domain to be optimized independently - the targeting domain ensures specific delivery while the IGF-1 variant maintains adequate half-life, resolving the contradiction between specificity and duration of action.
3Object-affected harmful factors
If existing treatments are used for brain injury, then some symptom relief is achieved, but oxidative damage and irreversible damage continue
Solution Approach 1:
The chimeric protein acts as an intermediary therapeutic agent that combines multiple functions: the Annexin A5 variant domain mediates targeting to injured tissue and reduction of oxidative damage, while the IGF-1 variant domain mediates activation of pro-survival signaling pathways. This intermediary protein simultaneously addresses both the harmful oxidative damage and promotes neural survival, resolving the contradiction between mitigating damage and ensuring survival.
Data Source
AI summary
Aspects of the present disclosure relate generally to kits and methods for treating acute central nervous systems disorders with chimeric proteins and pharmaceutical compositions comprising such chimeric proteins.